Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
Mary E.R. O'Brien, Luis G Paz-Ares, Sandrine I. Marreaud et al. · The Lancet Oncology · 2022
Cited by 774 works. doi:10.1016/s1470-2045(22)00518-6
Authors
- Mary E.R. O'Brien
- Luis G Paz-Ares
- Sandrine I. Marreaud
- Urania G. Dafni
- Kersti Oselin
- Libor Havel
- Emilio Esteban
- Dolores Isla
- Alex Martínez‐Martí
- Martin Faehling
- Masahiro Tsuboi
- Kazuhiko Nakagawa
- Jing Yang
- Ayman Samkari
- Steven M. Keller
- Murielle E.L. Mauer
- Nitish Jha
- Rolf Arno Stahel
- Benjamin Besse
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial
- Proportional Hazards Tests and Diagnostics Based on Weighted Residuals
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer